An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis

Sponsor
Tang-Du Hospital
Study ID
NCT06352502
Status
Unknown

Conditions

  • CNS Metastases
  • EGF-R Positive Non-Small Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Furmonertinib — DRUG
    Patients treated with Furmonertinib mesilate tablets orally

Study Details

EGFR mutation positive advanced NSCLC patients with CNS metastases were associated with poor prognosis. Furmonertinib showed promising CNS efficacy in doses of 80 mg orally once daily or higher in patients with EGFR T790M mutation positive NSCLC. This study aims to investigate the efficacy and safety of furmonertinib in the treatment of EGFR-sensitive mutation positive NSCLC patients with brain metastasis.

Key Dates

Start date
Jan 28, 2022
Status verified
Apr 2024
Primary completion
Sep 30, 2024
Completion
Sep 30, 2024

Study Design

Enrollment
30 participants (estimated)

Arms

  • Arm: Furmonertinib group
    Patients treated with Furmonertinib

Primary Outcome Measure

Intracranial Objective response rate [ Time Frame: Data obtained up until progression, or the last evaluable assessment in the absence of progression, will be assessed up to 2 years. ]

Central Contacts

Related Studies